Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients
Authors' conclusion
Better drug adherence and longer duration of denosumab treatment are associated with lower all-cause mortality risk among hip fracture patients after surgery.
Study context
- Population
- Patients newly diagnosed with osteoporosis and hip fracture between 2008 and 2019 who used denosumab after surgery, Taiwan
- Participants
- 21,316 patients
- Exposure
- Denosumab drug interval ≤ 7 months vs > 7 months; treatment duration over 1, 2 and 3 years vs < 1 year
- Outcome
- All-cause mortality risk
Methodological detailsnationwide population data (National Health Insurance Research Database (NHIRD), Taiwan)
- Nationwide population data (NHIRD, Taiwan)
Main finding
As reported in the abstract
All-cause mortality
Hazard ratio (95% CI)
≤ 7 MONTHSvs > 7 MONTHS
0.60(0.57 ≈0.64)
OVER 1 YEARvs < 1 YEAR
0.68(0.64 ≈0.73)
OVER 2 YEARSvs < 1 YEAR
0.48(0.43 ≈0.53)
OVER 3 YEARSvs < 1 YEAR
0.29(0.26 ≈0.33)
Observational data: associations, not effects.
Further findings
All-cause mortality after excluding short-term death
- Similar results
Cause-specific mortality (cancer, CVD)
- Good adherence and longer duration associated with reduced mortality due to cancer and CVD
Original publication
Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients. Osteoporos Int. Published 19 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →